Article Text

PDF
077
REAL-WORLD DATA ON ESLICARBAZEPINE ACETATE IN ELDERLY PATIENTS
  1. Camilla Karlsson1,
  2. Rob McMurray2,
  3. Rui Sousa3,
  4. Martin Holtkamp4
  1. 1 Eisai AB, Sweden
  2. 2 Eisai Europe Ltd
  3. 3 Bial, Portugal
  4. 4 Charité – Universitätsmedizin Berlin, Germany

Abstract

Purpose To assess eslicarbazepine acetate (ESL) in elderly patients included in the Eslicarbazepine acetate in Partial-Onset Seizures (EPOS) study.

Method Adult patients with uncontrolled partial-onset seizures receiving antiepileptic monotherapy, whose clinician had previously and independently decided to initiate ESL add-on therapy, were enrolled in the prospective, non-interventional EPOS study. A post hoc analysis was conducted for elderly patients (>60 years). Assessments included retention rate after 6 months, responder and seizure freedom rates, Quality of Life in Epilepsy Inventory-10 (QOLIE-10) and safety/tolerability.

Results Overall, 41 patients aged >60 years were included in EPOS (maximum age 83 years). After 6 months, retention, responder and seizure freedom rates were 78.0% (95% confidence interval [CI] 62.4–89.4%; n=41), 83.3% (95% CI 65.3–94.4%; n=30) and 56.3% (95% CI 37.7–73.6%; n=32), respectively. Mean QOLIE-10 total score decreased from 2.7 (n=28) at baseline to 2.2 (−14.5%; n=24) after 6 months. Twelve adverse events (AEs) were reported for six (14.6%) patients; most frequently, dizziness (4.9%) and allergic dermatitis (4.9%). No AE was reported in >5% of patients.

Conclusion ESL as add-on to antiepileptic monotherapy was efficacious and generally well tolerated when used to treat patients aged >60 years in a real-life setting.

Supported by Eisai.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.